KenSci operates as an advanced medical technology company that utilizes machine learning and artificial intelligence to power a risk prediction platform. The platform is designed to help healthcare providers identify potential clinical, financial, and operational risks in order to cut costs and save lives. “A library of pre-built models and modular solutions allows KenSci’s ML platform to integrate into existing workflows. With Explainable AI models for healthcare, KenSci is making risk-based prediction more efficient and accountable,” according to the company.
KenSci announced that it has closed $22 million in its Series B funding round. The funding round was led by Polaris Partners and had participation from a number of firms including: Ignition Partners, Osage University Partners, Mindset Ventures, and UL Ventures. After the latest round of funding, KenSci’s total funds raised increases to $30.5 million in its three-year existence.
KenSci Press Release:
KenSci, a Machine Learning and Artificial Intelligence powered, risk prediction platform for healthcare, announced today that it has closed $22 million in Series B funding. The funding round was led by Polaris Partners and witnessed strong participation from all existing investors including Ignition Partners, Osage University Partners, and Mindset Ventures. UL Ventures joined the round as a strategic investor, offering global reach and compliance expertise. The investment will further accelerate KenSci’s product roadmap and global expansion.
Commenting on the fundraising round, Samir Manjure, Co-Founder and CEO of KenSci, said, “In the last two years, we’ve singularly invested ourselves in building a platform that simplifies the way health systems look at their data and gain actionable, predictive insights to save lives and costs.
With this round of funding, we’re excited to take these capabilities to a global stage with partners who complement our capabilities and are committed to helping us drive this transformation across the care continuum.”
“KenSci has rapidly scaled to become one of the leading names in healthcare,” said Brian Chee, managing partner at Polaris Partners. “What KenSci has accomplished is extremely exciting and we’re thrilled to partner with them as they bring healthcare professionals both clinical and operational insights.”
Founded by Prof. Ankur Teredesai, from the University of Washington Tacoma, and Samir Manjure, a longtime Microsoft executive, KenSci’s risk prediction platform has helped some of the leading health systems across the globe align better to quadruple aim and improve the quality of care they provide at lower costs.
KenSci’s risk prediction platform is built on Azure ML, SQL and provides insights using Power BI. The platform ingests data from health sources, such as EMR, Claims, Billings, Pharmacy, Wearable, and Psychosocial data, to identify patterns that help uncover opportunities to save costs and lives.
With this round of funding, KenSci aims to align closely with health systems helping them overcome challenges in utilization, variation, and hospital operations with data-led predictive insights.
A three-year-old organization, this round brings KenSci’s total funding to $30.5 million. In 2018, KenSci was recognized as the winner of the Microsoft Health Innovation Awards for the best use of AI and ML.
KenSci’s machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci’s platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient generated sources. A library of pre-built models and modular solutions allows KenSci’s ML platform to integrate into existing workflows. With Explainable AI models for healthcare, KenSci is making risk based prediction more efficient and accountable.
KenSci was incubated at University of Washington’s Center for Data Science at UW Tacoma and designed on the cloud with help from Microsoft’s Azure4Research grant program.
KenSci is headquartered in Seattle, with offices in Singapore and Hyderabad. For more information, visit www.kensci.com.